$BIIB News AT&T, Yelp shares decline after ear
Post# of 102259
Posted On: 10/23/2014 10:37:01 AM
$BIIB News
AT&T, Yelp shares decline after earnings 5:48 p.m. Oct. 22, 2014 - Sue Chang
U.S. stocks wither; S&P 500 ends 4-day win steak 4:39 p.m. Oct. 22, 2014 - Carla Mozee
Updates, advisories and surprises 4:31 p.m. Oct. 22, 2014 - MarketWatch
Biogen shares drop on Tecfidera patient death 11:48 a.m. Oct. 22, 2014 - Russ Britt
Icahn says buying Apple is a ‘no-brainer’, and a first-ever for the VIX 11:37 a.m. Oct. 22, 2014 - Barbara Kollmeyer
Biogen Idec shares slump 7.6% 9:32 a.m. Oct. 22, 2014 - Sue Chang
Biogen shares turn lower; analyst says key MS drug sales missed expectations 8:37 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen shares turn lower, down 2.7% premarket after Q3 results 8:13 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen beats estimates on strong MS drug sales 7:49 a.m. Oct. 22, 2014 - MarketWatch.com
Biogen shares rally after beating profit expectations, raising outlook 7:15 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen shares gain 0.7% premarket after Q3 results 7:06 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen ups full-year adj. EPS outlook to $13.45-$13.55 vs. FactSet estimate $13.10 7:05 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 net EPS $3.62 vs. $2.05 a year ago 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 FactSet sales consensus $2.48 bln 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 sales $2.51 bln vs. $1.83 bln a year ago 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 adj. EPS $3.80 vs. FactSet consensus $3.45 7:02 a.m. Oct. 22, 2014 - Tomi Kilgore
Boeing, AT&T reports due Wednesday; Yahoo up late 6:48 p.m. Oct. 21, 2014 - Sue Chang
More than 1/3 of Dow stocks to report this week 5:30 a.m. Oct. 19, 2014 - Wallace Witkowski
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
US Stock Futures Rise Ahead Of Earnings, Economic Data 6:41 a.m. Today - benzinga.com
Leading Researchers Join Biogen Idec To Advance Drug Discovery For Neurodegenerative Diseases 6:31 a.m. Today - benzinga.com
EPS Strong; Revenues Weak 2:20 a.m. Today - Seeking Alpha
Watch for This Sign That the Correction Is Over 9:18 p.m. Oct. 22, 2014 - InvestorPlace.com
10-Q: BIOGEN IDEC INC. 5:01 p.m. Oct. 22, 2014 - Edgar Online - (EDG = 10Q, 10K)
Dow Ends Lower After Three-Day Rise 4:32 p.m. Oct. 22, 2014 - The Wall Street Journal Interactive Edition
Biotechs Show Fed Chief's Not Much Of A Stock Analyst 4:01 p.m. Oct. 22, 2014 - Investors Business Daily
Biogen Idec's (BIIB) CEO George Scangos on Q3 2014 Results - Earnings Call Transcript 2:51 p.m. Oct. 22, 2014 - Seeking Alpha
Despite Stock Market Rally Many Opportunities Still Exist 2:20 p.m. Oct. 22, 2014 - TheStreet.com
Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog 1:10 p.m. Oct. 22, 2014 - Zacks.com
3 Stocks Pulling The Drugs Industry Downward 1:03 p.m. Oct. 22, 2014 - TheStreet.com
Why Boeing Co, Biogen Idec Inc, and Discover Financial Services are Today’s 3 Worst Stocks 12:44 p.m. Oct. 22, 2014 - InvestorPlace.com
Why Biogen Idec (BIIB) Stock Is Tanking Today 12:39 p.m. Oct. 22, 2014 - TheStreet.com
Worries Cloud Biogen’s Results 10:35 a.m. Oct. 22, 2014 - The Wall Street Journal Interactive Edition
Biogen, Thermo Reports Disappoint; Abbott Accelerates 10:18 a.m. Oct. 22, 2014 - Investors Business Daily
Trade-Ideas: Biogen Idec (BIIB) Is Today's Unusual Social Activity Stock 9:52 a.m. Oct. 22, 2014 - TheStreet.com
Biogen drops after earnings call 9:44 a.m. Oct. 22, 2014 - Seeking Alpha
Biogen Idec (BIIB) Q3 2014 Results - Earnings Call Webcast 8:25 a.m. Oct. 22, 2014 - Seeking Alpha
Biogen Takes Breather on Earnings and MS Drug Sales 8:07 a.m. Oct. 22, 2014 - 247WallSt.com
Benzinga's Top #PreMarket Losers 7:43 a.m. Oct. 22, 2014 - benzinga.com
Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases 7:30 a.m. Today - BusinessWire - BZX
Regulatory Approval, Customer Safety Alert, Patient Support Program Launch, Earnings Releases, and Rating - Research Reports on Medtronic, Covidien, Biogen Idec, Baxter and Express Scripts 8:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals 8:01 a.m. Oct. 15, 2014 - BusinessWire - BZX
Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire 8:30 a.m. Oct. 13, 2014 - PR Newswire - PRF
Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe 3:01 p.m. Oct. 9, 2014 - Thomson Reuters ONE
CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 4:01 p.m. Oct. 8, 2014 - BusinessWire - BZX
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 5:34 p.m. Sept. 25, 2014 - BusinessWire - BZX
Results of Clinical Trials, New Drug Applications, Leadership Appointments, and Scheduled Earnings - Research Reports on Biogen, Salix, Express Scripts, Stryker and Shire 9:25 a.m. Sept. 23, 2014 - PR Newswire - PRF
Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index 8:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy 7:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec 2:01 a.m. Sept. 19, 2014 - Thomson Reuters ONE
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders 7:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp. 8:40 a.m. Sept. 15, 2014 - PR Newswire - PRF
Critical Alerts For U.S. Bancorp, Nuverra Environmental Solutions, Biogen, Deere and Philip Morris International Released By InvestorsObserver 9:31 a.m. Sept. 12, 2014 - PR Newswire - PRF
Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) 7:30 a.m. Sept. 12, 2014 - BusinessWire - BZX
New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients 7:30 a.m. Sept. 11, 2014 - BusinessWire - BZX
PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients 7:30 a.m. Sept. 11, 2014 - BusinessWire - BZX
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms 7:00 a.m. Sept. 10, 2014 - BusinessWire - BZX
AT&T, Yelp shares decline after earnings 5:48 p.m. Oct. 22, 2014 - Sue Chang
U.S. stocks wither; S&P 500 ends 4-day win steak 4:39 p.m. Oct. 22, 2014 - Carla Mozee
Updates, advisories and surprises 4:31 p.m. Oct. 22, 2014 - MarketWatch
Biogen shares drop on Tecfidera patient death 11:48 a.m. Oct. 22, 2014 - Russ Britt
Icahn says buying Apple is a ‘no-brainer’, and a first-ever for the VIX 11:37 a.m. Oct. 22, 2014 - Barbara Kollmeyer
Biogen Idec shares slump 7.6% 9:32 a.m. Oct. 22, 2014 - Sue Chang
Biogen shares turn lower; analyst says key MS drug sales missed expectations 8:37 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen shares turn lower, down 2.7% premarket after Q3 results 8:13 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen beats estimates on strong MS drug sales 7:49 a.m. Oct. 22, 2014 - MarketWatch.com
Biogen shares rally after beating profit expectations, raising outlook 7:15 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen shares gain 0.7% premarket after Q3 results 7:06 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen ups full-year adj. EPS outlook to $13.45-$13.55 vs. FactSet estimate $13.10 7:05 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 net EPS $3.62 vs. $2.05 a year ago 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 FactSet sales consensus $2.48 bln 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 sales $2.51 bln vs. $1.83 bln a year ago 7:03 a.m. Oct. 22, 2014 - Tomi Kilgore
Biogen Q3 adj. EPS $3.80 vs. FactSet consensus $3.45 7:02 a.m. Oct. 22, 2014 - Tomi Kilgore
Boeing, AT&T reports due Wednesday; Yahoo up late 6:48 p.m. Oct. 21, 2014 - Sue Chang
More than 1/3 of Dow stocks to report this week 5:30 a.m. Oct. 19, 2014 - Wallace Witkowski
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
US Stock Futures Rise Ahead Of Earnings, Economic Data 6:41 a.m. Today - benzinga.com
Leading Researchers Join Biogen Idec To Advance Drug Discovery For Neurodegenerative Diseases 6:31 a.m. Today - benzinga.com
EPS Strong; Revenues Weak 2:20 a.m. Today - Seeking Alpha
Watch for This Sign That the Correction Is Over 9:18 p.m. Oct. 22, 2014 - InvestorPlace.com
10-Q: BIOGEN IDEC INC. 5:01 p.m. Oct. 22, 2014 - Edgar Online - (EDG = 10Q, 10K)
Dow Ends Lower After Three-Day Rise 4:32 p.m. Oct. 22, 2014 - The Wall Street Journal Interactive Edition
Biotechs Show Fed Chief's Not Much Of A Stock Analyst 4:01 p.m. Oct. 22, 2014 - Investors Business Daily
Biogen Idec's (BIIB) CEO George Scangos on Q3 2014 Results - Earnings Call Transcript 2:51 p.m. Oct. 22, 2014 - Seeking Alpha
Despite Stock Market Rally Many Opportunities Still Exist 2:20 p.m. Oct. 22, 2014 - TheStreet.com
Biogen's Q3 Earnings Top Estimates, View Raised Again - Analyst Blog 1:10 p.m. Oct. 22, 2014 - Zacks.com
3 Stocks Pulling The Drugs Industry Downward 1:03 p.m. Oct. 22, 2014 - TheStreet.com
Why Boeing Co, Biogen Idec Inc, and Discover Financial Services are Today’s 3 Worst Stocks 12:44 p.m. Oct. 22, 2014 - InvestorPlace.com
Why Biogen Idec (BIIB) Stock Is Tanking Today 12:39 p.m. Oct. 22, 2014 - TheStreet.com
Worries Cloud Biogen’s Results 10:35 a.m. Oct. 22, 2014 - The Wall Street Journal Interactive Edition
Biogen, Thermo Reports Disappoint; Abbott Accelerates 10:18 a.m. Oct. 22, 2014 - Investors Business Daily
Trade-Ideas: Biogen Idec (BIIB) Is Today's Unusual Social Activity Stock 9:52 a.m. Oct. 22, 2014 - TheStreet.com
Biogen drops after earnings call 9:44 a.m. Oct. 22, 2014 - Seeking Alpha
Biogen Idec (BIIB) Q3 2014 Results - Earnings Call Webcast 8:25 a.m. Oct. 22, 2014 - Seeking Alpha
Biogen Takes Breather on Earnings and MS Drug Sales 8:07 a.m. Oct. 22, 2014 - 247WallSt.com
Benzinga's Top #PreMarket Losers 7:43 a.m. Oct. 22, 2014 - benzinga.com
Leading Researchers Join Biogen Idec to Advance Drug Discovery for Neurodegenerative Diseases 7:30 a.m. Today - BusinessWire - BZX
Regulatory Approval, Customer Safety Alert, Patient Support Program Launch, Earnings Releases, and Rating - Research Reports on Medtronic, Covidien, Biogen Idec, Baxter and Express Scripts 8:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Biogen Idec and Gretchen Rubin Unveil MS BlueprintTM, a New Online Tool to Help People with Multiple Sclerosis Attain Personal Goals 8:01 a.m. Oct. 15, 2014 - BusinessWire - BZX
Presentation of Clinical Data, FDA Approval, Notes Offering, and Market Activity - Research Reports on Biogen Idec, Arrowhead, Salix, HCA and Shire 8:30 a.m. Oct. 13, 2014 - PR Newswire - PRF
Sobi's collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe 3:01 p.m. Oct. 9, 2014 - Thomson Reuters ONE
CORRECTING and REPLACING Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 4:01 p.m. Oct. 8, 2014 - BusinessWire - BZX
Earnings Release Schedules, Data Presentation, Regulatory Approvals, and Strategic Collaboration - Research Reports on Covidien, Biogen, Amgen, Agios and Baxter 8:55 a.m. Oct. 1, 2014 - PR Newswire - PRF
Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014 5:34 p.m. Sept. 25, 2014 - BusinessWire - BZX
Results of Clinical Trials, New Drug Applications, Leadership Appointments, and Scheduled Earnings - Research Reports on Biogen, Salix, Express Scripts, Stryker and Shire 9:25 a.m. Sept. 23, 2014 - PR Newswire - PRF
Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index 8:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy 7:00 a.m. Sept. 23, 2014 - BusinessWire - BZX
Sobi expands Haemophilia development portfolio - elects to include potentially longer-acting Haemophilia A candidate in collaboration agreement with Biogen Idec 2:01 a.m. Sept. 19, 2014 - Thomson Reuters ONE
Ignyta to Participate in Precision Medicine Panel Discussions with Other Thought Leaders 7:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
Event Schedules, Survey Findings, Regulatory Filings, and Market Activity - Research Reports on Amgen, Biogen Idec, Salix, Covidien and Shire 8:50 a.m. Sept. 15, 2014 - PR Newswire - PRF
Health Care Sector Stocks Technical Review - Ampio Pharma, InterMune, Biogen Idec, Hologic, and CareFusion Corp. 8:40 a.m. Sept. 15, 2014 - PR Newswire - PRF
Critical Alerts For U.S. Bancorp, Nuverra Environmental Solutions, Biogen, Deere and Philip Morris International Released By InvestorsObserver 9:31 a.m. Sept. 12, 2014 - PR Newswire - PRF
Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) 7:30 a.m. Sept. 12, 2014 - BusinessWire - BZX
New Data from ENDORSE Show Positive Results Continued over Five Years with TECFIDERA® (Dimethyl Fumarate) in a Wide Range of Multiple Sclerosis Patients 7:30 a.m. Sept. 11, 2014 - BusinessWire - BZX
PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance of Efficacy and Safety in Multiple Sclerosis Patients 7:30 a.m. Sept. 11, 2014 - BusinessWire - BZX
New International Survey Finds MS Patients and Neurologists View Communication Positively, Yet Struggle to Discuss Key MS Symptoms 7:00 a.m. Sept. 10, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼